Grant: Banting Postdoctoral Fellowship Program
Direct Payment
$140,000.00
Structural characterization and optimization of ZMapp, an antibody cocktail efficacious against Ebola virus in nonhuman primates
FY 2014-15
Summary
Ebola virus (EBOV) kills up to 90% of humans and is one of the most deadly viruses. The outbreak of EBOV that has already, and continues to, ravage West Africa has been well-covered by the media and is described as "out of control" by the WHO and MSF. Unlike past outbreaks, this strain of EBOV has infected and killed residents, doctors and nurses alike, resulting in 2218 deaths out of 4366 reported cases as of September 12th, 2014. Ever since Nigeria, a global travel hub, became infected with EBOV through an imported case by air travel, there have been several scares from travellers which have fallen ill upon arrival in other countries, including false alarms in Canada. As a result, the current outbreak is undeniably a global problem, and it may be only a matter of time before there is further geographical spread.
No vaccines or treatments are approved for treating EBOV infections. However, 7 patients recently received ZMapp, a mixture of three antibodies against EBOV, under compassionate circumstances. Of these recipients, 5 survived and a recent study published by the applicant showed that ZMapp can reverse severe EBOV disease in monkeys. Therefore, ZMapp is currently the most promising experimental treatment against EBOV and its development needs to be prioritized. However, antibody therapy is expensive and the demand far exceeds current supplies. To address this problem, the applicant proposes to analyze the structure of ZMapp binding to EBOV, increase the effectiveness by creating antibodies which bind better to the virus, and test this improved mixture in monkeys. It is expected that lesser amounts of the improved antibodies will be needed to achieve the same levels of protection, and that the antibodies will be protective later in disease, thereby saving more lives. The knowledge gained will also help the scientific community by providing guidelines on the design of future antibody treatments against other diseases using a logical rationale.
Department
Program
Banting Postdoctoral Fellowship Program
Recipient
Location
China
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
315736
Name
Wong Gary C
Country
China
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Structural characterization and optimization of ZMapp, an antibody cocktail efficacious against Ebola virus in nonhuman primates
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Animal Research; Binding Affinity; Ebola Virus; Escape Mutant; Immune Response; Level 4 Biocontainment; Protein Crystallization; Structural Analysis; Virus-Host Interactions; Zmapp
Abstract
Ebola virus (EBOV) kills up to 90% of humans and is one of the most deadly viruses. The outbreak of EBOV that has already, and continues to, ravage West Africa has been well-covered by the media and is described as "out of control" by the WHO and MSF. Unlike past outbreaks, this strain of EBOV has infected and killed residents, doctors and nurses alike, resulting in 2218 deaths out of 4366 reported cases as of September 12th, 2014. Ever since Nigeria, a global travel hub, became infected with EBOV through an imported case by air travel, there have been several scares from travellers which have fallen ill upon arrival in other countries, including false alarms in Canada. As a result, the current outbreak is undeniably a global problem, and it may be only a matter of time before there is further geographical spread.
No vaccines or treatments are approved for treating EBOV infections. However, 7 patients recently received ZMapp, a mixture of three antibodies against EBOV, under compassionate circumstances. Of these recipients, 5 survived and a recent study published by the applicant showed that ZMapp can reverse severe EBOV disease in monkeys. Therefore, ZMapp is currently the most promising experimental treatment against EBOV and its development needs to be prioritized. However, antibody therapy is expensive and the demand far exceeds current supplies. To address this problem, the applicant proposes to analyze the structure of ZMapp binding to EBOV, increase the effectiveness by creating antibodies which bind better to the virus, and test this improved mixture in monkeys. It is expected that lesser amounts of the improved antibodies will be needed to achieve the same levels of protection, and that the antibodies will be protective later in disease, thereby saving more lives. The knowledge gained will also help the scientific community by providing guidelines on the design of future antibody treatments against other diseases using a logical rationale.
Competitiondate
201409
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Wong, Gary C
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~